Drugs / Nerispirdine
Nerispirdine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00811902 | Dec 2008 → Mar 2010 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00772525 | Sep 2008 → Jun 2009 | multiple sclerosis, neuritis, optic nerve disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00093275 | Oct 2004 → Dec 2005 | spinal cord injury | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nerispirdine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00811902 ↗ |
| Known as | HP184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00093275 ↗ |
| Known as | Nerispirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107762 ↗ |
| Known as | Nerispirdine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107762 ↗ |
| Modality | Small molecule | — CHEMBL2107762 ↗ |
| Route | Oral | “Administered Orally” NCT00093275 ↗ |